Figure 2
IP3 (a) but not IP1 (b) administered ICV to mice reduced immobility time in the FST and IP3 attenuated amphetamine-induced hyperlocomotion (c, d). (a, b) Immobility time in the FST 45 min following ICV administration of 150 μg IP3 (a) or 200 μg of IP1 (b) (or vehicle (aCSF)), each in liposomes. (a) *t-test: t(26)=5.65, P<0.03. (b) t-test: t(19)=1.59, P=0.22. (c, d) Amphetamine-induced hyperlocomotion. Thirty minutes following ICV administration of 150 μg IP3 in liposomes, mice were injected (i.p.) 1.5 mg kg−1 amphetamine (amphet) or saline, placed in an open-field box and their activity monitored for 30 min. (c) Two-way ANOVA: IP3 treatment: F(1,52)=55, P=0.01; amphetamine treatment: F(1,52)=8.67, P<0.01; ***amphetamine × IP3 interaction: F(1,51)=4.1, P<0.05. (d) Two-way ANOVA with repeated measures: IP3 treatment: F(6,46)=2.4, P=0.03; amphetamine treatment: F(6,46)=13.7, P<0.01. Two-way ANOVA for each time interval: *amphetamine/IP3 vs amphetamine/aCSF, P< at least 0.016. aCSF, artificial cerebrospinal fluid; ANOVA, analysis of variance; FST, forced swim test; IP, inositol phosphate; i.p., intraperitoneal; ICV, intracerebroventricularly; WT, wild type.
